# US 2022/0034766 A1 · Immunohistochemical staining for gsk-3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034766 A1
- Document ID: US20220034766A1
- Status: Published application
- Kind: A1
- Application number: 17/312,590
- Filed: 2019-12-12
- Published: 2022-02-03
- Earliest claimed: 2018-12-12
- Assignees: Actuate Therapeutics Inc.
- Applicants: Actuate Therapeutics, Inc.
- Inventors: Andrey UGOLKOV
- Web page: https://patentgrep.com/patent/US20220034766A1

## CPC

- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N 33/575: for cancer
- G01N 2001/302: {Stain compositions}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods of using immunohistochemical staining to identify cells expressing GSK-3 and use of such methods in treating disease are disclosed.

## Claims

### Claim 1

A method of treating a disease in a subject in need thereof, the method comprising: a) obtaining a tissue sample from the subject; b) measuring the expression level of a GSK-3 isoform in the sample, wherein the measuring is performed by immunohistochemical staining; c) comparing the expression level of the GSK-3 isoform in the tissue sample with the expression level of that GSK-3 isoform in a control sample; and d) administering an effective amount of an inhibitor of the GSK-3 isoform to the subject if an elevated expression level of the GSK-3 isoform in the tissue sample is detected when compared to the expression level of the GSK-3 isoform in the control sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the expression level of GSK-3 isoform is nuclear expression.

### Claim 3 (depends on 1)

The method of claim 1, wherein the expression level of GSK-3 isoform is cytoplasmic expression.

### Claim 4 (depends on 1)

The method of claim 1, wherein the expression level of GSK-3 isoform is nuclear and cytoplasmic expression.

### Claim 5 (depends on 1)

The method of claim 1, wherein the GSK-3 isoform is GSK-3β.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inhibitor of the GSK-3 isoform is 9-ING-41, tideglusib, or LY2090314.

### Claim 7 (depends on 6)

The method of claim 6, wherein the inhibitor of the GSK-3 isoform is 9-ING-41.

### Claim 8 (depends on 1)

The method of claim 1, wherein the GSK-3 isoform is GSK-3α.

### Claim 9 (depends on 1)

The method of claim 1, wherein the disease is cancer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the tissue sample is a tumor sample.

### Claim 11 (depends on 9)

The method of claim 9, wherein the cancer is breast cancer, brain cancer, esophagus cancer, stomach cancer, lung cancer, liver cancer, kidney cancer, thyroid gland cancer, spleen cancer, pancreas cancer, large bowel cancer, skin cancer, ovarian cancer, uterus cancer, prostate cancer, bladder cancer, testicular cancer, osteosarcoma, fibrosarcoma.

### Claim 12 (depends on 1)

The method of claim 1, wherein the disease is a malignant lymphoproliferative disorder.

### Claim 13 (depends on 1)

The method of claim 1, wherein the disease is pulmonary fibrosis or pleural fibrosis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the immunohistochemical staining comprises a step comprising counterstaining the tissue sample with a counterstain for about 30 seconds to about 8 minutes.

### Claim 15 (depends on 14)

The method of claim 14, wherein the counterstain is hematoxylin and the counterstaining is for about 30 seconds.

### Claim 16

An immunohistochemical method for detecting elevated expression of a GSK-3 isoform in a biological sample from an individual through an antigen-antibody reaction comprising, (1) contacting said biological sample with a first antibody specific for a GSK-3 isoform to give a antibody-contacted biological sample; (2) contacting said first antibody-contacted biological sample with a secondary antibody specific for said first antibody, wherein said secondary antibody has an enzymatic activity; (3) treating the product of (2) with a chromogenic substrate for said enzymatic activity; and (4) counterstaining the product of (3) with a counterstain for up to 8 minutes.

### Claim 17 (depends on 16)

The method of claim 16, wherein the counterstain is hematoxylin.

### Claim 18 (depends on 17)

The method of claim 17 wherein the counterstaining with hematoxylin is performed for up to 4 minutes.

### Claim 19 (depends on 17)

The method of claim 17 wherein the counterstaining with hematoxylin is performed for up to 2 minutes.

### Claim 20 (depends on 17)

The method of claim 17 wherein the counterstaining with hematoxylin is performed for up to 1 minute.

### Claim 21 (depends on 17)

The method of claim 17 wherein the counterstaining with hematoxylin is performed for up to 30 seconds.

### Claim 22 (depends on 17)

The method of claim 17 wherein the counterstaining with hematoxylin is performed for up to 10 seconds.

### Claim 23 (depends on 16)

The method of claim 16, wherein the enzymatic activity of the secondary antibody is peroxidase activity.

### Claim 24 (depends on 16)

The method of claim 16, wherein the enzymatic activity of the secondary antibody is alkaline phosphatase activity.

### Claim 25 (depends on 23)

The method of claim 23, wherein the chromogenic substrate is a peroxidase substrate.

### Claim 26 (depends on 24)

The method of claim 24, wherein the chromogenic substrate is an alkaline phosphatase substrate.

### Claim 27 (depends on 16)

The method of claim 16, wherein the first antibody is a monoclonal antibody.

### Claim 28 (depends on 16)

The method of claim 16, wherein the second antibody is a monoclonal antibody.

### Claim 29

A kit for use in immunohistochemical staining for GSK-3, wherein said kit comprises
(a) a GSK-3 inhibitor;
(b) a GSK-3 specific antibody;
(c) a secondary antibody that is specific for the GSK-3 specific antibody, wherein the secondary antibody also has a conjugated enzymatic activity;
(d) a chromogenic substrate for the enzymatic activity of the secondary antibody;
(e) a counterstain;
(f) and instructions for use of the kit.

### Claim 30 (depends on 29)

The kit of claim 29, wherein the GSK-3 inhibitor is 9-ING-41, tideglusib, LY2090314, CHIR-99021, CHIR-98014, SB216763, SB415286, AR-A014418, CG701338, or CG202796

### Claim 31 (depends on 30)

The kit of claim 30, wherein the GSK-3 inhibitor is 9-ING-41.

### Claim 32 (depends on 29)

The kit of claim 29, wherein the GSK-3 specific antibody is a GSK-3beta specific monoclonal antibody.

### Claim 33 (depends on 29)

The kit of claim 29, wherein conjugated enzymatic activity is peroxidase activity or alkaline phosphatase activity.

### Claim 34 (depends on 33)

The kit of claim 33, wherein conjugated enzymatic activity is peroxidase activity.

### Claim 35 (depends on 29)

The kit of claim 29, wherein chromogenic substrate is diaminobenzidine (DAB), 3-Amino-9-ethylcarbazole (AEC), 5-bromo-4-chloro-3-indolyl phosphate/tetranitroblue tetrazolium (BCIP/TNBT), or Naphthol AS-MX phosphate+Fast Blue BB.

### Claim 36 (depends on 35)

The kit of claim 35, wherein chromogenic substrate is diaminobenzidine (DAB).

### Claim 37 (depends on 29)

The kit of claim 29, wherein the counterstain is hematoxylin or methyl green.

### Claim 38 (depends on 37)

The kit of claim 37, wherein the counterstain is hematoxylin.

### Claim 39 (depends on 29)

The kit according to claim 29, for use in a method of treating a disease in a subject in need thereof, the method comprising: a) obtaining a tissue sample from the subject; b) measuring the expression level of a GSK-3 isoform in the sample, wherein the measuring is performed by immunohistochemical staining; c) comparing the expression level of the GSK-3 isoform in the tissue sample with the expression level of that GSK-3 isoform in a control sample; and d) administering an effective amount of an inhibitor of the GSK-3 isoform to the subject if an elevated expression level of the GSK-3 isoform in the tissue sample is detected when compared to the expression level of the GSK-3 isoform in the control sample.
